NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells

Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is a Food and Drug Administration–approved drug for treatment of patients with late-stage prostate cancer and is currently under clinical study for early-sta...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Biol Chem
Glavni autori: Farah, Elia, Li, Chaohao, Cheng, Lijun, Kong, Yifan, Lanman, Nadia A., Pascuzzi, Pete, Lorenz, Gabrielle Renee, Zhang, Yanquan, Ahmad, Nihal, Li, Lang, Ratliff, Tim, Liu, Xiaoqi
Format: Artigo
Jezik:Inglês
Izdano: American Society for Biochemistry and Molecular Biology 2019
Teme:
Cell Biology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6544854/
https://ncbi.nlm.nih.gov/pubmed/30940724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.RA118.006983
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items